Mutation News and Research

RSS

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Avila Therapeutics, Inc. a biotechnology company developing targeted covalent drugs that treat diseases through protein silencing, announced that it has achieved a significant goal in its alliance with Clovis Oncology, Inc.

9 Jun 2011

Research provides new insights into how cilia are assembled on the cell surface

Body cells detect signals that control their behavior through tiny hairs on the cell surface called cilia. Serious diseases and disorders can result when these cilia do not work properly.

9 Jun 2011

Adjuvant combination generates memory CD8 T cells which could kill infected cells

Researchers at National Jewish Health have discovered how to prime a second arm of the immune system to potentially boost influenza vaccine effectiveness. A combination of two adjuvants, chemicals used to boost the effectiveness of some vaccines, induced CD8, or killer, T cells to join antibodies in response to influenza infection.

9 Jun 2011

Valuable insight into how people develop B-cell lymphoma

Researchers from the University of Sheffield have discovered valuable insight into how people develop B-cell lymphoma, one of the most common cancers in the UK.

9 Jun 2011

Autism caused by hundreds of different genetic mutations: Study

New research shows that autism is not caused by one or two gene defects but probably by hundreds of different mutations, many of which arise spontaneously. This comes from the study that has examined the genes of more than 1,000 families.

9 Jun 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

New research on spinal muscular atrophy

Spinal muscular atrophy (SMA) is the leading genetic cause of death in children under 2, with no treatment other than supportive care. In the Proceedings of the National Academy of Sciences, researchers at Children's Hospital Boston show how loss or mutation of the SMA gene causes progressive muscle degeneration and weakness, and suggest a promising approach to treating the condition, sometimes referred to as a "Lou Gehrig's disease of babies."

8 Jun 2011

As health care technology advances, costs increase

The device industry has launched an aggressive campaign to avoid tighter Food and Drug Administration rules that would help generate the information needed to show whether newer devices are actually superior to the ones they replace.

8 Jun 2011

Increased blood clotting tendency linked to elevated bowel cancer risk

Back in the mid 19th century, a French doctor, Armand Trousseau, discovered a connection between cancer and thrombosis - the formation of often dangerous blood clots that can lead to venous occlusion.

7 Jun 2011

Faults in p53 gene could help predict beneficial drug combination for ovarian cancer

FAULTS in a gene commonly inactivated in many different types of cancer could be used to predict which drug combination ovarian cancer patients are most likely to benefit from, according to results presented at the American Society for Clinical Oncology.

7 Jun 2011

Non-steroidal, oral contraceptive for men

Researchers at Columbia University Medical Center are honing in on the development of what may be the first non-steroidal, oral contraceptive for men. Tests of low doses of a compound that interferes with retinoic acid receptors (RARs), whose ligands are metabolites of dietary vitamin A, showed that it caused sterility in male mice.

7 Jun 2011

Cancer risk assessment in Lynch syndrome

Among various genetic mutations for individuals with Lynch syndrome, a hereditary cancer syndrome that carries a high risk of colon cancer and an above-normal risk of other cancers, researchers have identified mutations associated with a lower cancer risk and mutations associated with an increased risk for ovarian and endometrial cancer, according to a study in the June 8 issue of JAMA, a theme issue on cancer.

6 Jun 2011

New study shows Bisphenol A exposure through diet has been underestimated

A new University of Missouri study shows that the exposure to the controversial chemical Bisphenol A (BPA) through diet has been underestimated by previous lab tests.

6 Jun 2011

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in advanced non-small cell lung cancer (NSCLC) that showed promising clinical activity in patients with progressive disease.

6 Jun 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced positive clinical data with the Company's IMGN901 (lorvotuzumab mertansine) product candidate as featured in an oral presentation at the ASCO 2011 Annual Meeting in Chicago.

6 Jun 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced efficacy and safety data from the BRIM3 trial, a large, randomized, multi-center Phase 3 clinical study of vemurafenib in patients with previously untreated metastatic melanoma with the BRAFV600 mutation.

6 Jun 2011

New skin cancer drug brings hope

A new drug for the dreaded cancer melanoma is in the horizon. It is called Vemurafenib. This is a class of drug that cancer researchers are applauding today at the American Society of Clinical Oncology's annual meeting in Chicago.

5 Jun 2011

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Customizing targeted therapies to each tumor's molecular characteristics, instead of a one-size-fits-all approach by tumor type, may be more effective for some types of cancer, according to research conducted by The University of Texas MD Anderson Cancer Center.

4 Jun 2011

Study links loss of PTEN gene with patient's response to melanoma therapy

Genetic analysis of the tumors from patients with advanced melanoma can clue researchers in to how well patients will respond to a therapy that targets the growth-promoting protein called BRAF, a researcher from the Perelman School of Medicine at the University of Pennsylvania will report on Monday, June 6 at the annual meeting of the American Society of Clinical Oncology.

4 Jun 2011

HRT reduces risk of breast cancer in women with BRCA mutations after ovary removal

Women with the BRCA1 or BRCA2 gene mutations, which are linked to a very high risk of breast and ovarian cancer, can safely take hormone-replacement therapy (HRT) to mitigate menopausal symptoms after surgical removal of their ovaries, according to new research from the Perelman School of Medicine at the University of Pennsylvania which will be presented Monday, June 6 during the American Society for Clinical Oncology's annual meeting.

4 Jun 2011

Mutation News and Research

Clovis, Avila select CO-1686 drug candidate for EGFR Mutant-Selective Inhibitor program

Research provides new insights into how cilia are assembled on the cell surface

Adjuvant combination generates memory CD8 T cells which could kill infected cells

Valuable insight into how people develop B-cell lymphoma

Autism caused by hundreds of different genetic mutations: Study

NYU Cancer Institute scientists present new research findings at ASCO 2011

New research on spinal muscular atrophy

As health care technology advances, costs increase

Increased blood clotting tendency linked to elevated bowel cancer risk

Faults in p53 gene could help predict beneficial drug combination for ovarian cancer

Non-steroidal, oral contraceptive for men

Cancer risk assessment in Lynch syndrome

New study shows Bisphenol A exposure through diet has been underestimated

Synta presents ganetespib Phase 2 trial results in advanced non-small cell lung cancer at ASCO 2011

ImmunoGen's IMGN901 Phase I trial data on multiple myeloma presented at ASCO 2011

Positive results from Plexxikon's vemurafenib Phase 2 and 3 trial against metastatic melanoma

New skin cancer drug brings hope

Customizing targeted therapies to each tumor's molecular characteristics may effectively treat cancer

Study links loss of PTEN gene with patient's response to melanoma therapy

HRT reduces risk of breast cancer in women with BRCA mutations after ovary removal

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News